

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Berg Aaron</u>  (Last) (First) (Middle) <u>C/O AMARIN PHARMA, INC.</u> <u>440 US HIGHWAY 22</u>  (Street) <u>BRIDGEWATER NJ</u> <u>08807</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>AMARIN CORP PLC</u> [ <u>AMRN</u> ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>CHIEF COMMERCIAL OFFICER</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>12/31/2020</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares <sup>(1)</sup>	12/31/2020		M <sup>(2)</sup>		1,528	A	(3)	217,570	D	
Ordinary Shares <sup>(1)</sup>	12/31/2020		M <sup>(2)</sup>		1,528	A	(3)	219,098	D	
Ordinary Shares <sup>(1)</sup>	12/31/2020		F <sup>(4)</sup>		1,506	D	\$5.23	217,592 <sup>(5)</sup>	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units <sup>(6)</sup>	\$0.00	12/31/2020		M			1,528	(2)	(3)	Ordinary Shares <sup>(1)</sup>	1,528	\$0.00	12,221	D	
Restricted Stock Units <sup>(6)</sup>	\$0.00	12/31/2020		M			1,528	(2)	(3)	Ordinary Shares <sup>(1)</sup>	1,528	\$0.00	12,221	D	
Stock Option (Right to Buy)	\$5.03	01/04/2021		A		193,500		(7)	01/04/2031	Ordinary Shares <sup>(1)</sup>	193,500	\$0.00	193,500	D	
Restricted Stock Units <sup>(6)</sup>	\$0.00	01/04/2021		A		143,300		(8)	(3)	Ordinary Shares <sup>(1)</sup>	143,300	\$0.00	143,300	D	

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 220,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "2011 Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding \$400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-eighth vesting event occurred on December 31, 2020. The performance criteria related to the remaining 50% tranche has not yet been formally deemed achieved; such tranche has not lapsed as a result of achieving the other two tranches.
3. Not applicable.
4. Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.
5. Please see the section titled "Remarks" below for additional information.
6. Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion.
7. On January 4, 2021, the Reporting Person was granted an option to purchase 193,500 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "2020 Plan" and, together with the 2011 Plan, the "Plans"). The shares subject to this option shall vest and become exercisable over four years, with 25% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 12 calendar quarters on the last day of each March, June, September and December.
8. On January 4, 2021, the Reporting Person was granted 143,300 RSUs under the 2020 Plan. These RSUs vest in three equal installments on each of December 31, 2021, December 31, 2022 and December 31, 2023.

Remarks:

The equity grants referenced above were supported by recommendations of the Company's independent compensation consultant and approved by the Remuneration Committee of the Company's Board of Directors. As of the date of this Form 4, the Reporting Person owns or holds the right to acquire an aggregate of 1,411,482 Ordinary Shares of the Issuer in the form of Ordinary Shares, stock options and RSUs outstanding under the Plans, including but not limited to certain performance-based RSUs that are earned only if certain pre-defined operational milestones are achieved and, in certain cases, then vest only if the recipient remains with the company for an extended period of time.

/s/ Joseph T. Kennedy, by power  
of attorney

01/05/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.